DPHARMA Stock Splits - Duopharma Biotech Bhd

Price: 1.2 MYR -2.44%

Market Cap: 1.2B MYR

The company executed a 4-for-3 stock split, meaning that for every 3 shares held, investors received 4 new shares.

Before the split, DPHARMA traded at 2.61 per share. Afterward, the share price was about 1.9077.

The adjusted shares began trading on Sep 6, 2021. This was DPHARMA's 5th stock split, following the previous one in Jun 14, 2018.

Sep 6, 2021

4-for-3

Jun 14, 2018

322782-for-138335

Jun 18, 2015

746-for-553

Jul 12, 2004

196106-for-89139

Oct 8, 2003

6-for-5

Pre-Split Price

2.61

Post-Split Price

1.9077

Adjust Price

Sep 6, 2021

4-for-3

Jun 14, 2018

322782-for-138335

Jun 18, 2015

746-for-553

Jul 12, 2004

196106-for-89139

Oct 8, 2003

6-for-5

Duopharma Biotech Bhd
Stock Splits History

Logarithmic

Sep 6, 2021

Split 4-for-3

x1.3333333333333

Pre-Split Price

1.9053

Post-Split Price

1.9077

Adjust Price

Jun 14, 2018

Split 322782-for-138335

x2.3333357429429

Pre-Split Price

0.9162

Post-Split Price

0.8787

Adjust Price

Jun 18, 2015

Split 746-for-553

x1.3490054249548

Pre-Split Price

0.7039

Post-Split Price

0.7026

Adjust Price

Jul 12, 2004

Split 196106-for-89139

x2.2000022436868

Pre-Split Price

N/A

Post-Split Price

0.3604

Adjust Price

Oct 8, 2003

Split 6-for-5

x1.2

Pre-Split Price

N/A

Post-Split Price

0.3604

Adjust Price

Global
Stock Splits Monitor

Forward Splits

Reverse Splits

Adjust Price

Date	Company		Split	Pre-Split Price	Post-Split Price
Mar 28, 2025		Yellow Hat Ltd OTC:YLLWF YLLWF Valuation & Fundamental Analysis Stock Splits Performance Benchmark	2-for-1 x2	16.93 8.3482 USD	8.465 8.465 USD
Mar 25, 2025		CMC Metals Ltd XTSX:CMB CMB Valuation & Fundamental Analysis Stock Splits Performance Benchmark	1-for-10 /10	0.02 0.2 CAD	0.25 0.25 CAD
Mar 25, 2025		Rent.com.au Ltd ASX:RNT RNT Valuation & Fundamental Analysis Stock Splits Performance Benchmark	63-for-62 x1.0161290322581	0.021 0.0207 AUD	0.018 0.018 AUD
Mar 25, 2025	U	US Critical Metals Corp OTC:USCMF USCMF Valuation & Fundamental Analysis Stock Splits Performance Benchmark	1-for-2 /2	0.06 0.15 USD	0.1127 0.1127 USD
Mar 25, 2025		CMC Metals Ltd F:ZM5P ZM5P Valuation & Fundamental Analysis Stock Splits Performance Benchmark	1-for-10 /10	0.0038 0.038 EUR	0.009 0.009 EUR

Duopharma Biotech Bhd
Glance View

Market Cap

1.2B MYR

Industry

Pharmaceuticals

Duopharma Biotech Bhd.is an investment holding company, which engages in the manufacturing and distribution of pharmaceutical products. The company is headquartered in Klang, Selangor. The company went IPO on 2002-07-18. The Company, through its subsidiaries is engaged in manufacturing, distribution, importing and exporting of pharmaceutical products and medicines. The firm also engaged in research and development of pharmaceutical products. Its subsidiaries include Duopharma (M) Sendirian Berhad, Duopharma Manufacturing (Bangi) Sdn. Bhd., Duopharma Marketing Sdn. Bhd., Duopharma Consumer Healthcare Sdn. Bhd., Duopharma HAPI Sdn. Bhd., Duopharma Innovation Sdn. Bhd., Unique Pharmacy (Penang) Sdn. Bhd., Sentosa Pharmacy Sdn. Bhd., Duopharma Manufacturing (Glenmarie) Sdn. Bhd., Negeri Pharmacy Sdn. Bhd., Duopharma (Singapore) Pte. Ltd. and DB (Philippines), Inc.

View DPHARMA Analysis

DPHARMA Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US

	Franklin Covey Co NYSE:FC	28.03 USD -0.25%
	Mohawk Industries Inc NYSE:MHK	113.74 USD -2.94%
	Ardmore Shipping Corp NYSE:ASC	10.21 USD 1.69%
	ASGN Inc NYSE:ASGN	63.02 USD -1.87%
	Skyworks Solutions Inc NASDAQ:SWKS	64.12 USD -3.29%
	Weatherford International PLC NASDAQ:WFRD	53.1 USD -2.91%

	Johnson & Johnson NYSE:JNJ	163.71 USD 0.36%
	Bank of America Corp NYSE:BAC	41.25 USD -3.08%
	Mastercard Inc NYSE:MA	540.61 USD -3.04%
	Salesforce Inc NYSE:CRM	269.97 USD -2.82%
	Abbvie Inc NYSE:ABBV	205.29 USD 1.27%
	Home Depot Inc NYSE:HD	358.15 USD -1.26%

	Arista Networks Inc NYSE:ANET	77.94 USD -1.29%
	Visa Inc NYSE:V	342.85 USD -2%
	Texas Pacific Land Corp NYSE:TPL	1 305.71 USD -1.97%
	KLA Corp NASDAQ:KLAC	673.6 USD -3.77%
	Manhattan Associates Inc NASDAQ:MANH	173.48 USD -0.77%
	Monolithic Power Systems Inc NASDAQ:MPWR	579.89 USD -3.58%

Duopharma Biotech Bhd
KLSE:DPHARMA

DPHARMA's latest stock split occurred on Sep 6, 2021

Duopharma Biotech Bhd
Stock Splits History

Global
Stock Splits Monitor

Duopharma Biotech Bhd
Glance View

Company

Help

Tools

Stocks

	ServiceNow Inc NYSE:NOW	797.76 USD -3.62%
	EOG Resources Inc NYSE:EOG	126.59 USD -0.11%
	Monster Beverage Corp NASDAQ:MNST	57.86 USD -1.23%
	Applied Materials Inc NASDAQ:AMAT	145.06 USD -1.77%
	Airbnb Inc NASDAQ:ABNB	120.69 USD -3.95%
	Synopsys Inc NASDAQ:SNPS	437.95 USD -1.86%

52 Week Range	1.13 1.4
Price Target

Duopharma Biotech Bhd KLSE:DPHARMA

DPHARMA's latest stock split occurred on Sep 6, 2021

Duopharma Biotech Bhd Stock Splits History

Global Stock Splits Monitor

Duopharma Biotech Bhd Glance View

Company

Help

Tools

Stocks

Duopharma Biotech Bhd
KLSE:DPHARMA

Duopharma Biotech Bhd
Stock Splits History

Global
Stock Splits Monitor

Duopharma Biotech Bhd
Glance View